Abstract
Background With the emergence of the Omicron variant, an increasing proportion of SARS-CoV-2 associated deaths have a principal cause of death other than COVID-19. In France, between Nov. 1, 2021 --July 31, 2022, in addition to 33,353 deaths with the principal cause of COVID-19, there were 9,638 deaths with a confirmed SARS-CoV-2 infection with a principal cause of death other than COVID-19 (as well as SARS-CoV-2-associated deaths with an undetected SARS-CoV-2 infection).
Methods We examined the relation between mortality for COVID-19, mortality for other causes, and ICU admissions with a SARS-CoV-2-infection in adults aged over 60y in France.
Results The number of deaths with principal causes other than COVID-19 in France between July 2021-June 2022 was greater than the corresponding number between July 2020-June 2021 by 20,860 (95% CI (11241,30421)) after adjusting for pre-pandemic trends in mortality (compared to the increase of 3,078 in the number of deaths with a SARS-CoV-2 infection with principal causes other than COVID-19 between the two time periods). During the period of Omicron circulation (Nov. 1, 2021 - Nov. 13, 2022), there was a strong association between the rates of ICU admission with a SARS-CoV-2 infection in adults aged over 60y and (a) rates of COVID-19 deaths (correlation=0.96 (0.92,0.97)); (b) rates of mortality with principal causes other than COVID-19 (correlation=0.89 (0.82,0.94)). Proportions of ICU admissions for causes other than COVID-19 among all ICU admissions with a SARS-CoV-2 infection in older adults were lower during the periods when rates of COVID-19 disease in the community were higher.
Conclusions The significant increase in mortality with principal causes other than COVID-19, as well as the decreases in the proportions of ICU admissions for causes other than COVID-19 among all ICU admissions with a SARS-CoV-2 infection in older adults during the periods when rates of COVID-19 disease in the community were higher suggest under-detection of Omicron infections in associated complications that did not manifest themselves as COVID-19, which is related to the treatment of SARS-CoV-2 infection in those complications.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
edmigo3{at}gmail.com
Additional material on SARS-CoV-2-associated mortality with principal causes other when COVID-19 (including refs. 9-11) added.
Data Availability
This study is based on aggregate, de-identified data available through refs. 3,7,8,12-16.
https://opendata.idf.inserm.fr/cepidc/covid-19/telechargements
https://www.insee.fr/fr/statistiques/4931039?sommaire=4487854#tableau-figure1
https://www.insee.fr/fr/statistiques/2381472#graphique-Donnes
